{"name":"Federation Francophone de Cancerologie Digestive","slug":"federation-francophone-de-cancerologie-digestive","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Ipilimumab Injection","genericName":"Ipilimumab Injection","slug":"ipilimumab-injection","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Atezolizumab Injection","genericName":"Atezolizumab Injection","slug":"atezolizumab-injection","indication":"Metastatic non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"FOLFIRI.3","genericName":"FOLFIRI.3","slug":"folfiri-3","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"FOLFOX4 or XELOX","genericName":"FOLFOX4 or XELOX","slug":"folfox4-or-xelox","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"LV5FU2 or capecitabine","genericName":"LV5FU2 or capecitabine","slug":"lv5fu2-or-capecitabine","indication":"Colorectal cancer (metastatic and adjuvant settings)","status":"phase_3"},{"name":"LV5FU2 or capectitabine","genericName":"LV5FU2 or capectitabine","slug":"lv5fu2-or-capectitabine","indication":"Colorectal cancer (metastatic and adjuvant)","status":"phase_3"},{"name":"Oxaliplatin intra-arteriel","genericName":"Oxaliplatin intra-arteriel","slug":"oxaliplatin-intra-arteriel","indication":"Colorectal cancer with hepatic metastases (intra-arterial administration)","status":"phase_3"},{"name":"Oxaliplatin intravenous","genericName":"Oxaliplatin intravenous","slug":"oxaliplatin-intravenous","indication":"Colorectal cancer (metastatic and adjuvant settings)","status":"phase_3"},{"name":"induction chemotherapy (mDCF)","genericName":"induction chemotherapy (mDCF)","slug":"induction-chemotherapy-mdcf","indication":"Metastatic or locally advanced gastric cancer (induction therapy)","status":"phase_3"},{"name":"liposomal cisplatin","genericName":"liposomal cisplatin","slug":"liposomal-cisplatin","indication":"Ovarian cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Aflibercept Injection","genericName":"Aflibercept Injection","slug":"aflibercept-injection","indication":"Other","status":"marketed"},{"name":"radiochemotherapy","genericName":"radiochemotherapy","slug":"radiochemotherapy","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Ipilimumab Injection","genericName":"Ipilimumab Injection","slug":"ipilimumab-injection","phase":"phase_3","mechanism":"Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","indications":["Metastatic melanoma","Advanced or metastatic colorectal cancer (in combination with nivolumab)","Metastatic non-small cell lung cancer (in combination with nivolumab)"],"catalyst":""},{"name":"Aflibercept Injection","genericName":"Aflibercept Injection","slug":"aflibercept-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atezolizumab Injection","genericName":"Atezolizumab Injection","slug":"atezolizumab-injection","phase":"phase_3","mechanism":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.","indications":["Metastatic non-small cell lung cancer (NSCLC)","Metastatic urothelial carcinoma","Hepatocellular carcinoma","Gastric or gastroesophageal junction adenocarcinoma","Colorectal cancer (in combination with chemotherapy)"],"catalyst":""},{"name":"FOLFIRI.3","genericName":"FOLFIRI.3","slug":"folfiri-3","phase":"phase_2","mechanism":"FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"FOLFOX4 or XELOX","genericName":"FOLFOX4 or XELOX","slug":"folfox4-or-xelox","phase":"phase_3","mechanism":"FOLFOX4 and XELOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents.","indications":["Metastatic colorectal cancer","Adjuvant treatment of stage III colorectal cancer","Gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"LV5FU2 or capecitabine","genericName":"LV5FU2 or capecitabine","slug":"lv5fu2-or-capecitabine","phase":"phase_3","mechanism":"LV5FU2/capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting cancer cell replication.","indications":["Colorectal cancer (metastatic and adjuvant settings)","Gastric cancer","Breast cancer","Pancreatic cancer"],"catalyst":""},{"name":"LV5FU2 or capectitabine","genericName":"LV5FU2 or capectitabine","slug":"lv5fu2-or-capectitabine","phase":"phase_3","mechanism":"LV5FU2 and capecitabine are fluoropyrimidine chemotherapy agents that inhibit thymidylate synthase and get incorporated into DNA/RNA to disrupt cancer cell replication.","indications":["Colorectal cancer (metastatic and adjuvant)","Gastric cancer","Breast cancer"],"catalyst":""},{"name":"Oxaliplatin intra-arteriel","genericName":"Oxaliplatin intra-arteriel","slug":"oxaliplatin-intra-arteriel","phase":"phase_3","mechanism":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, delivered directly into the hepatic artery to maximize local concentration in liver tumors.","indications":["Colorectal cancer with hepatic metastases (intra-arterial administration)"],"catalyst":""},{"name":"Oxaliplatin intravenous","genericName":"Oxaliplatin intravenous","slug":"oxaliplatin-intravenous","phase":"phase_3","mechanism":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis.","indications":["Colorectal cancer (metastatic and adjuvant settings)","Gastric cancer","Pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"induction chemotherapy (mDCF)","genericName":"induction chemotherapy (mDCF)","slug":"induction-chemotherapy-mdcf","phase":"phase_3","mechanism":"mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers.","indications":["Metastatic or locally advanced gastric cancer (induction therapy)","Esophageal cancer (induction therapy)"],"catalyst":""},{"name":"liposomal cisplatin","genericName":"liposomal cisplatin","slug":"liposomal-cisplatin","phase":"phase_3","mechanism":"Liposomal cisplatin works by releasing cisplatin, a platinum-based chemotherapy drug, in a targeted manner to kill cancer cells.","indications":["Ovarian cancer","Non-small cell lung cancer","Bladder cancer","Stomach cancer"],"catalyst":""},{"name":"radiochemotherapy","genericName":"radiochemotherapy","slug":"radiochemotherapy","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPT3QtSW9WUDlLWFdjLVM2UElWMnVXUENlZ28xVDZBcTlOMUZhdEQ3dnhtLUtiZ3N0LU9Md0l4SDNycDZpWUhUWGZKcGhBQXpQdzdlQmNjdDRmeUFPMGFEdWxZVF8xaWo2a0FlUE9uTFA3VV9kaEhYc0l6N2pqUENiRGxXS0NLWTc1VHJYSEZ3Qkd5NUE2ak42MVdxWlcwZE16eDRxbw?oc=5","date":"2021-08-03","type":"trial","source":"Cancer Therapy Advisor","summary":"Study Supports Maintenance Over Sequential Treatment Strategy in Metastatic Pancreatic Cancer - Cancer Therapy Advisor","headline":"Study Supports Maintenance Over Sequential Treatment Strategy in Metastatic Pancreatic Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE93NTdxbFE4Y2ViUmRpLUlDbEpwRm9KSXpKNHFGODBnc2xVak9LMzhtT0FhaWw0NXZkMUhBd0R2Rnkzdl84Z3hnTGVHWlRsaTMtaWx4N0xOTENBX25XME5yNkRZejdNTl9ZQ3YtUnd5N2VhRHN0R3R1bW5tTQ?oc=5","date":"2012-05-16","type":"trial","source":"Pharmafile","summary":"Merck KGaA’s colon cancer drug fails trial - Pharmafile","headline":"Merck KGaA’s colon cancer drug fails trial","sentiment":"negative"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":10,"marketed":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}